Legend:
CC = Baltimore Convention Center,
H = Hilton Baltimore
* = applied session ! = JSM meeting theme
|
|
|
|
357
|
Tue, 8/1/2017,
10:30 AM -
11:15 AM
|
CC-Halls A&B
|
|
SPEED: Biopharmaceutical Statistics — Contributed Poster Presentations
|
|
Biopharmaceutical Section , Section on Statistical Learning and Data Science
|
|
Chair(s): Jessi Cisewski, Yale University
|
|
The Speed portion will take place during Session 214526
|
|
1:
|
Tradeoffs of a Randomize, Then Consent Approach to Improving Cluster Participation Rates in Cluster Randomize Trials
—
Abigail Shoben, The Ohio State University
|
|
2:
|
Sample Size for Joint Testing Cause-Specific Hazard and Overall Hazard in the Presence of Competing Risks
—
Qing Yang, Duke University ; Gang Li, University of California, Los Angeles
|
|
3:
|
Accounting for Baseline Covariates and Missing Data in Regulatory Trials with Longitudinal Designs
—
Elizabeth Colantuoni, Johns Hopkins University ; Jon Steingrimsson, Johns Hopkins University ; Aidan McDermott, Johns Hopkins University ; Michael Rosenblum, Johns Hopkins University
|
|
4:
|
Robust Feature Selection and Cell Line Classification with Electric Cell-Substrate Impedance Sensing Data
—
Megan Gelsinger, Cornell University ; David S Matteson, Cornell University ; Laurie Tupper, Williams College
|
|
5:
|
Comparing Biomarker-Guided Treatment Strategies Using Local Posterior Predictive Benefit
—
Meilin Huang, The University of Texas MD Anderson Cancer Center ; Brian P. Hobbs, The University of Texas MD Anderson Cancer Center
|
|
6:
|
A Comparison of Assay Platforms Using Correlation Coefficients in the Presence of Repeated Measurements
—
Qinlei Huang, Merck & Co. ; Radha Railkar, Merck & Co. ; Anita Lee, Merck & Co.
|
|
8:
|
On Measure of Surrogacy for Biomarkers in Medical Research.
—
Rui Zhuang, University of Washington ; Ying Qing Chen, Fred Hutchinson Cancer Research Center
|
|
9:
|
Discriminant Analysis (DA) Based Methods in Safety Evaluation
—
Angang Zhang, Merck ; Richard Baumgartner, Merck ; William W Wang, Merck & Co Inc
|
|
10:
|
On the Estimation of Risk Difference in the Presence of Continuous Baseline Covariates
—
Hua Ma, Merck ; Robin Mogg, Merck
|
|
11:
|
Power Comparison of Tests of Restricted Mean Survival Time with Log-Rank Test and Generalized Wilcoxon Test Under Various Survival Distributions
—
Musashi Fukuda, Astellas Pharma Inc. ; Yutaka Matsuyama, Department of Biostatistics, School of Public Health, The University of Tokyo
|
|
12:
|
Optimal Designs for Pharmacokinetic Studies Analyzed Using Non-Compartmental Methods
—
Helen Barnett, Lancaster University ; Thomas Jaki, Lancaster University ; Helena Geys, Janssen Pharmaceutica ; Tom Jacobs, Janssen Pharmaceutica
|
|
13:
|
Statistical Considerations in Delayed-Start Design to Demonstrate Disease Modification Effect in Neurodegenerative Disorders
—
Jun Zhao, AbbVie Inc. ; Deli Wang, AbbVie, Inc. ; Weining Z Robieson, AbbVie Inc.
|
|
14:
|
Placebo-Based Multiple Imputation Methods for Sensitivity Analysis in Recurrent Event Data
—
Rui Yang, Chiltern International Inc
|
|
15:
|
Sample Size Calculation for the Generalized Poisson Regression Model Comparing Two Rates of Recurrent Events
—
Kimitoshi Ikeda, Amgen Astellas BioPharma K.K.
|
|
16:
|
Sample Size Calculation to Support Local Submission
—
Zhuqing Yu, AbbVie ; Bidan Huang, AbbVie ; Jun Zhao, AbbVie Inc. ; lu cui, Abbvie
|
|
17:
|
An Examination of the Association Between Alcohol and Dementia in a Longitudinal Study
—
Tingting Hu, Florida State University ; Dan McGee, Florida State University ; Elizabeth Slate, Florida State University
|
|
18:
|
Design and Statistical Analysis of Method Transfer Studies for Biotechnology Products
—
Meiyu Shen, C DER, FDA ; Lixin Xu, FDA
|
